Effect of cytostatic proline rich polypeptide-1 on tumor suppressors of inflammation pathway signaling in chondrosarcoma

Galoian,Karina; Luo,Shihua; Qureshi,Amir; Patel,Parthik; Price,Rachel; Morse,Ashlyn   S.; Chailyan,Gor; Abrahamyan,Silva; Temple,H.   T.

doi:10.3892/mco.2016.1010

Effect of cytostatic proline rich polypeptide-1 on tumor suppressors of inflammation pathway signaling in chondrosarcoma

Authors:
- Karina Galoian
- Shihua Luo
- Amir Qureshi
- Parthik Patel
- Rachel Price
- Ashlyn S. Morse
- Gor Chailyan
- Silva Abrahamyan
- H. T. Temple
View Affiliations

Affiliations: Department of Orthopaedics, University of Miami, Miller School of Medicine, Miami, FL 33136, USA, Buniatian Institute of Biochemistry Academy of Sciences of Armenia, Yerevan 0014, Armenia, Center for Translational Research, Nova Southeastern University, Fort Lauderdale, FL 33314, USA
Published online on: September 2, 2016 https://doi.org/10.3892/mco.2016.1010
Pages: 618-624

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cytokines produced in the tumour microenvironment exert an important role in cancer pathogenesis and in the inhibition of disease progression. Cancer of the cartilage is termed metastatic chondrosarcoma; however, the signaling events resulting in mesenchymal cell transformation to sarcoma have yet to be fully elucidated. The present study aimed to characterize the cytokine expression profile in the human JJ012 chondrosarcoma cell line, as well as the effect of cytostatic proline‑rich polypeptide‑1 (PRP‑1). Western blot experiments demonstrated that the levels of suppressor of cytokine signaling 3 (SOCS3) were upregulated in chondrocytes compared with chondrosarcoma cells. Addition of PRP‑1 restored the expression of the tumor suppressors, SOCS3 and ten‑eleven‑translocation methylcytosine dioxygenase 1 and 2 (TET1/2), in a dose‑responsive manner. It is known that methylation of histone H3K9 was eliminated from the promoters of the inflammation‑associated genes. PRP‑1 inhibited H3K9 demethylase activity with an IC50 (concentration required to give half‑maximal inhibition) value of 3.72 µg/ml in the chondrosarcoma cell line. Data obtained from ELISA experiments indicated that the expression of interleukin‑6 (IL‑6) in chondrosarcoma cells was 86‑fold lower compared with that in C28 chondrocytes. In the present study, a 53‑fold downregulation of IL‑6 expression in co‑culture of chondrosarcoma cells and C28 chondrocytes was identified as well. Downregulation of IL‑6 expression has been documented in numerous other tumor types, although the reasons for this have not been fully established. In chondrosarcoma, IL‑6 manifests itself as an anti‑inflammatory agent and, possibly, as an anti‑tumorigenic factor. To explore protein‑DNA interactions leading to such differences, a gel‑shift chemiluminescent assay was performed. Gel shifts were observed for chondrosarcoma and chondrocytes in the lanes that contained nuclear cell extract and oligo‑IL‑6 DNA. Notably, the DNA‑protein complexes in C28 chondrocytes were markedly larger compared with those in chondrosarcoma cells. The mechanisms that underpin such differences, and characterization of the interacting proteins, remain to be fully elucidated.

View Figures

View References

1	Landskron G, De la Fuente M, Thuwajit P, Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014:1491852014. View Article : Google Scholar : PubMed/NCBI
2	Mirra J: Bone Tumors: Clinical, radiologic, and pathologic correlations. Lea and Febiger; Philadelphia, PA: 1989
3	Galoian K, Scully S, McNamara G, Flynn P and Galoyan A: Antitumorigenic effect of brain proline rich polypeptide-1 in human chondrosarcoma. Neurochem Res. 34:2117–2121. 2009. View Article : Google Scholar : PubMed/NCBI
4	Galoian K, Scully S and Galoyan A: Myc-oncogene inactivating effect by proline rich polypeptide (PRP-1) in chondrosarcoma JJ012 cells. Neurochem Res. 34:379–385. 2009. View Article : Google Scholar : PubMed/NCBI
5	Galoian K, Temple HT and Galoyan A: Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by mTOR and cMyc inhibition in high grade chondrosarcoma. Neurochem Res. 36:812–818. 2011. View Article : Google Scholar : PubMed/NCBI
6	Galoian KA, Temple HT and Galoyan A: Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors. Tumour Biol. 32:745–51. 2011. View Article : Google Scholar : PubMed/NCBI
7	Galoian K, Temple HT and Galoyan A: mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via Pl3K-AKT and Pl3K-RAS-MAPK feedback loops. Tumour Biol. 33:885–90. 2012. View Article : Google Scholar : PubMed/NCBI
8	Galoian K, Qureshi A, D'ippolito G, Schiller PC, Molinari M, Johnstone AL, Brothers SP, Paz AC and Temple HT: Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1. Int J Oncol. 47:465–472. 2015.PubMed/NCBI
9	Galoian K, Qureshi A, Wideroff G and Temple HT: Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells. Mol Clin Oncol. 3:171–178. 2015.PubMed/NCBI
10	Galoian K, Guettouche T, Issac B, Qureshi A and Temple HT: Regulation of onco and tumor suppressor miRNAs by mTORC 1 inhibitor PRP-1 in human chondrosarcoma. Tumour Biol. 35:2335–2341. 2014. View Article : Google Scholar : PubMed/NCBI
11	Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, et al: Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013. View Article : Google Scholar : PubMed/NCBI
12	He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, et al: Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 333:1303–1307. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C and Zhang Y: Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 333:1300–1303. 2011. View Article : Google Scholar : PubMed/NCBI
14	Chmielecki J and Meyerson M: DNA sequencing of cancer: What have we learned? Annu Rev Med. 65:63–79. 2014. View Article : Google Scholar : PubMed/NCBI
15	Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, et al: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 19:17–30. 2011. View Article : Google Scholar : PubMed/NCBI
16	Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L and Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009. View Article : Google Scholar : PubMed/NCBI
17	Suijker J, Oosting J, Koornneef A, Struys EA, Salomons GS, Schaap FG, Waaijer CJ, Wijers-Koster PM, Briaire-de Bruijn IH, Haazen L, et al: Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget. 6:12505–12519. 2015. View Article : Google Scholar : PubMed/NCBI
18	Haseeb A, Makki MS and Haqqi TM: Modulation of ten-eleven translocation 1 (TET1), Isocitrate Dehydrogenase (IDH) expression, α-Ketoglutarate (α-KG), and DNA hydroxymethylation levels by interleukin-1β in primary human chondrocytes. J Biol Chem. 289:6877–6885. 2014. View Article : Google Scholar : PubMed/NCBI
19	Deel MD, Li JJ, Crose LE and Linardic CM: A review: Molecular aberrations within hippo signaling in bone and soft-tissue sarcomas. Front Oncol. 5:1902015. View Article : Google Scholar : PubMed/NCBI
20	Tiet TD, Hopyan S, Nadesan P, Gokgoz N, Poon R, Lin AC, Yan T, Andrulis IL, Alman BA and Wunder JS: Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol. 168:321–30. 2006. View Article : Google Scholar : PubMed/NCBI
21	Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS and Johnson RL: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA. 107:1437–1442. 2010. View Article : Google Scholar : PubMed/NCBI
22	Eisinger-Mathason TS, Mucaj V, Biju KM, Nakazawa MS, Gohil M, Cash TP, Yoon SS, Skuli N, Park KM, Gerecht S and Simon MC: Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proc Natl Acad Sci USA. 112:E3402–E3411. 2015. View Article : Google Scholar : PubMed/NCBI
23	Mohamed AD, Tremblay AM, Murray GI and Wackerhage H: The Hippo signal transduction pathway in soft tissue sarcomas. Biochim Biophys Acta. 1856:121–129. 2015.PubMed/NCBI
24	Li R, Cai L, Ding J, Hu CM, Wu TN and Hu XY: Inhibition of hedgehog signal pathway by cyclopamine attenuates inflammation and articular cartilage damage in rats with adjuvant-induced arthritis. J Pharm Pharmacol. 67:963–971. 2015. View Article : Google Scholar : PubMed/NCBI
25	Nakashima H, Nakamura M, Yamaguchi H, Yamanaka N, Akiyoshi T, Koga K, Yamaguchi K, Tsuneyoshi M, Tanaka M and Katano M: Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res. 66:7041–7049. 2006. View Article : Google Scholar : PubMed/NCBI
26	Zacharias WJ, Li X, Madison BB, Kretovich K, Kao JY, Merchant JL and Gumucio DL: Hedgehog is an anti-inflammatory epithelial signal for the intestinal lamina propria. Gastroenterology. 138:2368–2377, 2377.e1-e4. 2010. View Article : Google Scholar : PubMed/NCBI
27	Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, et al: A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 519:57–62. 2015. View Article : Google Scholar : PubMed/NCBI
28	Duh QY and Grossman RF: Thyroid growth factors, signal transduction pathways, and oncogenes. Surg Clin North Am. 75:421–437. 1995. View Article : Google Scholar : PubMed/NCBI
29	Barclay JL, Anderson ST, Waters MJ and Curlewis JD: SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer. 124:1756–1766. 2009. View Article : Google Scholar : PubMed/NCBI
30	Revel M: Growth regulatory functions of IL6 and antitumor effects. Res Immunol. 143:769–773. 1992. View Article : Google Scholar : PubMed/NCBI
31	Givon T, Slavin S, Haran-Ghera N, Michalevicz R and Revel M: Antitumor effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and in cell cultures. Blood. 79:2392–2398. 1992.PubMed/NCBI
32	Basolo F, Fiore L, Pollina L, Fontanini G, Conaldi PG and Toniolo A: Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: in vitro and in vivo studies. Clin Cancer Res. 4:381–387. 1998.PubMed/NCBI
33	Mulé JJ, McIntosh JK, Jablons DM and Rosenberg SA: Antitumor activity of recombinant interleukin 6 in mice. J Exp Med. 171:629–636. 1990. View Article : Google Scholar : PubMed/NCBI
34	Ragazzi M, Ciarrocchi A, Sancisi V, Gandolfi G, Bisagni A and Piana S: Update on anaplastic thyroid carcinoma: Morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol. 2014:7908342014. View Article : Google Scholar : PubMed/NCBI
35	Tseleni-Balafouta S, Arvanitis D, Kakaviatos N and Paraskevakou H: Primary myxoid chondrosarcoma of the thyroid gland. Arch Pathol Lab Med. 112:94–96. 1988.PubMed/NCBI
36	Galoian K, Guettouche T, Issac B, Navarro L and Temple HT: Lost miRNA surveillance of Notch, IGFR pathway-road to sarcomagenesis. Tumour Biol. 35:483–492. 2014. View Article : Google Scholar : PubMed/NCBI
37	Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S and Longacre M: Cancer development, progression, and therapy: An epigenetic overview. Int J Mol Sci. 14:21087–21113. 2013. View Article : Google Scholar : PubMed/NCBI
38	Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, et al: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 150:1135–1146. 2012. View Article : Google Scholar : PubMed/NCBI
39	Fan M, He X and Xu X: Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells. Mol Med Rep. 12:4837–4842. 2015.PubMed/NCBI
40	Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, et al: TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol. 16:8892015. View Article : Google Scholar : PubMed/NCBI
41	Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, Zhao D, Liu Y, Wang C, Zhang X, et al: Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 525:389–393. 2015. View Article : Google Scholar : PubMed/NCBI
42	Jo D, Liu D, Yao S, Collins RD and Hawiger J: Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med. 11:892–898. 2005. View Article : Google Scholar : PubMed/NCBI
43	Qin H, Holdbrooks AT, Liu Y, Reynolds SL, Yanagisawa LL and Benveniste EN: SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J Immunol. 189:3439–3448. 2012. View Article : Google Scholar : PubMed/NCBI
44	Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L and Natarajan R: Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA. 105:9047–9052. 2008. View Article : Google Scholar : PubMed/NCBI
45	Blanchard F, Duplomb L, Baud'huin M and Brounais B: The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev. 20:19–28. 2009. View Article : Google Scholar : PubMed/NCBI
46	Clark JC, Akiyama T, Dass CR and Choong PF: New clinically relevant, orthotopic mouse models of human chondrosarcoma with spontaneous metastasis. Cancer Cell Int. 10:202010. View Article : Google Scholar : PubMed/NCBI